Arrowhead Pharmaceuticals ARWR
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$8.00M (11 inflow days, 9 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 34.1% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 6.52% to 8.20% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| FMR | Mutual Fund | 2026/Q3 | +1,317,882 | 6.6% |
| Morgan Stanley | Public Company | 2026/Q3 | +750,314 | 1.3% |
| Morgan Stanley Investment Management Inc. | Mutual Fund | 2026/Q3 | +750,314 | 1.3% |
| Artal Group S.A. | VC/PE Fund | 2026/Q3 | +575,000 | 1.6% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +427,631 | 4.3% |
| BlackRock | Mutual Fund | 2026/Q3 | +310,287 | 10.7% |
| Global Alpha Capital Management Ltd. | Mutual Fund | 2026/Q3 | +259,374 | 0.2% |
| Davern Capital Partners, LP | Hedge Fund | 2026/Q3 | +229,300 | 0.2% |
| Norges Bank Investment Management | Sovereign Wealth Fund | 2026/Q3 | +2,192,072 | 2.8% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q3 | +1,203,770 | 1.0% |
| Holocene Advisors, LP | Hedge Fund | 2026/Q3 | +1,106,177 | 0.8% |
| FMR | Mutual Fund | 2026/Q3 | +771,066 | 5.7% |
| Avoro Capital Advisors LLC | Hedge Fund | 2026/Q3 | +655,556 | 8.0% |
| Dimensional Fund Advisors | Mutual Fund | 2026/Q3 | +573,077 | 0.8% |
| Two Sigma Investments, LP | Hedge Fund | 2026/Q3 | +544,809 | 0.4% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 17 Aug 2026 | Adeoye Olukotun | Independent Director | Open Market Disposition | -2,000 | $86.96 | 31,600 |
| 17 Aug 2026 | Michael Perry | Independent Director | Open Market Disposition | -11,600 | $87.30 | 103,640 |
| 14 Jun 2026 | Matthew Cohen | Director | Other Acquisition | +11,882 | – | 11,882 |
| 11 May 2026 | Hongbo Lu | Independent Director | Open Market Disposition | -2,970 | $76.88 | 41,816 |
| 11 May 2026 | Hongbo Lu | Independent Director | Intent to Sell (Form 144) | -315,202 | – | – |
| 22 Apr 2026 | James Hamilton | Chief Medical Officer and Head of R&D | Automatic Disposition | -10,000 | $75.00 | 226,958 |
| 22 Apr 2026 | James Hamilton | Chief Medical Officer and Head of R&D | Intent to Sell (Form 144) | -10,000 | – | – |
| 21 Apr 2026 | Daniel Apel | Chief Financial Officer | Automatic Disposition | -13,095 | $71.92 | 12,905 |
| 21 Apr 2026 | Daniel Apel | Chief Financial Officer | Intent to Sell (Form 144) | -13,095 | – | – |
| 4 Mar 2026 | James Hamilton | Chief Medical Officer and Head of R&D | Automatic Disposition | -10,000 | $64.19 | 236,958 |
| 5 Jan 2026 | Daniel Apel | Chief Financial Officer | Other Acquisition | +75,000 | – | 175,000 |
| 5 Jan 2026 | James Hamilton | Chief Medical Officer and Head of R&D | Other Acquisition | +75,000 | – | 246,958 |
| 5 Jan 2026 | Patrick O'Brien | COO & Secretary | Other Acquisition | +75,000 | – | 208,750 |
| 5 Jan 2026 | Patrick O'Brien | COO & Secretary | Other Disposition | -2,500 | – | 263,658 |
| 4 Jan 2026 | James Hamilton | Chief Medical Officer and Head of R&D | Automatic Disposition | -40,164 | $68.00 | 171,958 |
| 4 Jan 2026 | James Hamilton | Chief Medical Officer and Head of R&D | Intent to Sell (Form 144) | -40,164 | $63.10 | – |
| 4 Jan 2026 | Patrick O'Brien | COO & Secretary | Automatic Disposition | -49,493 | $68.00 | 341,158 |
| 1 Jan 2026 | Christopher Anzalone | Chairperson & CEO | Automatic Disposition | -13,187 | $66.39 | 3,792,739 |
| 30 Dec 2025 | Patrick O'Brien | COO & Secretary | Other Disposition | -2,800 | – | 341,158 |
| 28 Dec 2025 | Christopher Anzalone | Chairperson & CEO | Derivative Exercise and Sale | -51,726 | $69.33 | 3,805,926 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 11,583,518 | 8.2% | 8.5 |
| 15 Oct 2026 | 10,959,276 | 7.8% | 5.4 |
| 30 Sep 2026 | 10,760,463 | 7.6% | 4.0 |
| 15 Sep 2026 | 9,272,290 | 6.6% | 5.2 |
| 31 Aug 2026 | 9,426,449 | 6.7% | 8.8 |
| 14 Aug 2026 | 9,207,426 | 6.5% | 7.8 |
No comments yet — be the first to weigh in on ARWR.
Sign in to join the discussion.